DOJ Gives Preliminary Nod To $69 Billion Merger of CVS Health (CVS, $79.49) and Aetna (AET, $203.72)
U.S. drugstore chain CVS Health's plans to acquire prescription insurer Aetna got the preliminary approval from the U.S. Department of Justice (DOJ). CVS wants to make the acquisition through $69 billion in cash and stock, as revealed by the company in December. If the deal gets through the final stage of regulatory approval, the new merged entity can potentially emerge as a major player in disrupting the healthcare industry and how U.S. consumers access medical care.
Aetna announced on Sept. 27 that it is selling its Medicare Part D drug plan business to WellCare Health Plans, thereby mitigating regulators’ concerns about the conflict of interest between CVS' and Aetna's Medicare Part D plans should the firms merge.
The deal would help CVS gain more data from Aetna about people’s health conditions, which it can use to market its products to individuals and advise people on prevention/precautionary measures while also potentially boosting attendance at its walk-in clinics, MinuteClinics. While CVS currently is the pharmacy benefits manager to Aetna, the merger would only solidify the partnership since it potentially eliminates the possibility of Aetna switching to any other benefits manager in future.
CVS CEO Larry Merlo said that the two companies will create a model that's "easier to use, less expensive and puts people at the center of their care." That’s something even regulators seem to agree with: Assistant Attorney General Makan Delrahim said in a statement that CVS-Aetna merger could reduce Americans’ health care costs and improve the quality of patient care. Medical costs have increased by an average of 5.5 percent or more every year since 2007, according to consulting firm PwC. Recently, the DOJ also green-lighted health insurer Cigna's acquisition of pharmacy benefits manager Express Scripts. Such regulatory approvals are apparently intended to lower healthcare costs for Americans.
CVS’s expected merger with Aetna comes in the face of drugstores facing serious competition from online retailers; Amazon’s acquisition of online pharmacy delivery business PillPack this year potentially adds to the head-to-head.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVS's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for CVS moved out of oversold territory on August 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 20 of the 29 cases the stock moved higher. This puts the odds of a move higher at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 01, 2026. You may want to consider a long position or call options on CVS as a result. In 60 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on August 31, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 31 of 50 cases over the following month. The odds of a continued upward trend are 62%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 231 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 69 cases where CVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
The 10-day moving average for CVS crossed bearishly below the 50-day moving average on August 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
CVS broke above its upper Bollinger Band on September 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CVS entered a downward trend on September 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.519) is normal, around the industry mean (3.776). P/E Ratio (24.976) is within average values for comparable stocks, (152.490). CVS's Projected Growth (PEG Ratio) (0.222) is slightly lower than the industry average of (0.929). CVS has a moderately high Dividend Yield (0.028) as compared to the industry average of (0.020). P/S Ratio (0.292) is also within normal values, averaging (0.595).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement